DIHEXA
Potent preclinical nootropic in rats; zero published human evidence of cognitive efficacy.
Updated:
Affiliate link to this product’s page on Peptira. We may earn a commission at no extra cost to you. Code KAREL. Disclosure
Quick summary
DIHEXA is a stabilized angiotensin IV analog developed as a pro-cognitive candidate. In rats, it improves maze learning and hippocampal synaptogenesis was reported. There are no human clinical trials of the compound. Marketing of “a thousand times BDNF” is often based on unreviewed extrapolations or problematic papers.
Studied for
How it works
Signaling via the angiotensin IV / HGF-c-Met system was proposed; treat the mechanism as a hypothesis and avoid citing the retracted c-Met paper as fact.
What the research says
JPET / PubMed 23055539 — AngIV analogs in rats. Later studies in APP/PS1 models (e.g., PubMed 34827486). Alzheimer’s Drug Discovery Foundation and independent reviews underscore the absence of human data.
Evidence level
D — animals only
What's most reported
- Rats: improved spatial memory in impairment models
- Forums: focus/memory — anecdotal
Common side effects
Unknown in humans. Theoretical concern of mitogenesis if HGF/c-Met were activated in a sustained manner — not quantified.
Combines / does not combine
Do not stack with other experimental “neurogenics” without a basis.
Frequently asked questions
None on cognitive efficacy have been published.
The oral form does not imply clinical safety.
Keep exploring
Keep learning
Related peptides
Educational content. This is not medical advice or a usage guideline. Research products are not approved medications unless otherwise indicated.